Open access
Open access
Powered by Google Translator Translator

Small Randomized Trial Suggests a Benefit from Metformin as Adjunctive Therapy in Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma

16 Sep, 2019 | 00:46h | UTC

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Commentary: Metformin Repurposed: Boosts Survival in TKI-Treated Lung Cancer – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.